Detalles de la búsqueda
1.
Short-, mid- and long-term efficacy of dupilumab in moderate to severe atopic dermatitis: a real life multicenter Italian study on 2576 patients.
Clin Exp Dermatol
; 2024 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38860563
2.
Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
J Eur Acad Dermatol Venereol
; 38(2): 340-353, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37669868
3.
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study.
J Eur Acad Dermatol Venereol
; 2024 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38284131
4.
Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
J Dtsch Dermatol Ges
; 22(1): 34-42, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37926830
5.
Long-term psychological outcome of patients with moderate-to-severe atopic dermatitis continuously treated with Dupilumab: Data up to 3 years.
Exp Dermatol
; 32(6): 852-858, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36856013
6.
Impact on health-related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate-to-severe atopic dermatitis.
Dermatol Ther
; 35(5): e15407, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35218275
7.
Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
Dermatol Ther
; 35(10): e15670, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35762118
8.
Risankizumab shows high efficacy and maintenance in improvement of response until week 52.
Dermatol Ther
; 35(5): e15378, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35156278
9.
Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
Dermatol Ther
; 35(1): e15166, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34676662
10.
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study.
Acta Derm Venereol
; 101(11): adv00605, 2021 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34596230
11.
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study.
BMC Health Serv Res
; 21(1): 924, 2021 Sep 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34488749
12.
Dupilumab in HIV-positive patients with atopic dermatitis: a long-term follow-up patient and a literature review.
Dermatol Online J
; 27(8)2021 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34755964
13.
Efficacy of dupilumab in prurigo nodularis in elderly patient.
Dermatol Ther
; 33(1): e13201, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31856368
14.
Breaking tradition: A case report on successfully treating psoriasis in a patient with bipolar disorders using biologics, without discontinuing lithium.
Bipolar Disord
; 26(1): 98-102, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38054521
15.
Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.
J Am Acad Dermatol
; 90(5): 1031-1034, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38199282
16.
Safety of dupilumab in patients with cancer.
J Eur Acad Dermatol Venereol
; 2024 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38372448
17.
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series.
J Eur Acad Dermatol Venereol
; 2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38421043
18.
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis.
Exp Dermatol
; 32(9): 1591-1594, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37395012
19.
"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors.
Exp Dermatol
; 32(12): 2187-2188, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36541075
20.
Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres.
Clin Exp Dermatol
; 48(12): 1376-1378, 2023 11 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37596961